The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?-Reference-Cited by-同舟云学术

The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?

Published:2015-02 Issue:1 Volume:25 Page:2-12
ISSN:1096-6374
Container-title:Growth Hormone & IGF Research
language:en
Short-container-title:Growth Hormone & IGF Research

Author:

Crudden Caitrin,Ilic Marina,Suleymanova Naida,Worrall Claire,Girnita Ada,Girnita Leonard^ORCID

Funder

Swedish Research Council

Swedish Cancer Society

Children Cancer Society

Crown Princess Margareta's Foundation for the Visually Impaired

Welander Finsen Foundation

King Gustaf V Jubilee Foundation

Stockholm Cancer Society

Stockholm County

Karolinska Institutet

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference158 articles.

1. Growth factors and cancer;Aaronson;Science,1991

2. Structure and function of the type 1 insulin-like growth factor receptor;Adams;Cell. Mol. Life Sci.,2000

3. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma;Ahlen;Clin. Cancer Res.,2005

4. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination;Ahmed;Biochemistry,2011

5. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2;Ahn;J. Biol. Chem.,2004

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Growth Factor Receptor Implications in Breast Cancer: Prospects for Their Molecular Transactivation in the Future and Obstacles for Target Therapy;Interdisciplinary Cancer Research;2024

2. TRPV1 inhibition suppresses non-small cell lung cancer progression by inhibiting tumour growth and enhancing the immune response;Cellular Oncology;2023-10-30

3. IGF-1R targeting in cancer – does sub-cellular localization matter?;Journal of Experimental & Clinical Cancer Research;2023-10-20

4. Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness;Molecular Cancer Research;2023-08-16

5. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer;Gynecologic Oncology;2023-03